For those who thought the Martin Shkreli saga was over now that he’s serving a federal prison term, think again. More: Made for TV: Shkreli running his drug company from prison cell, WSJ says Source: fierce
read moreA major Allergan pipeline candidate may have failed phase 3 on Wednesday, but investors cheered the news. The reason? They’re anticipating extreme measures—namely, a company split-up that would make the most of its aesthetics business. More: Allergan investors, rooting for
read moreCaught by an outcry over high insulin prices, Eli Lilly has unveiled an authorized generic version of its Humalog insulin. But the other two major providers, Sanofi and Novo Nordisk, don’t seem to have any plans to follow suit in
read moreThe FDA has again lashed out at a Canadian company that it has been feuding with for more than a decade for helping U.S. consumers get drugs on the cheap. Its clients, however, are shrugging off the warning that the
read moreLouisiana is moving forward with a flat-rate payment system for purchasing hepatitis C drugs, and so far, the field’s top players are on board. Washington state has its own, similar plans—and if the “Netflix” model works, others may well follow.
read moreAllergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression. More: Allergan's rapastinel fails to hit key targets in depression trials Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals